NCT06072690Recruiting
Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
The Impact of Dual Bronchodilation on Respiratory and Cardiovascular Systems in Patients With Newly Diagnosed Moderate-to-severe Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g. bronchitis, bronchiolitis) and/or alveoli (emphysema) that lead to persistent, often progressive, airflow obstruction. It is a major cause of disability and death worldwide. Moreover, people with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. In the past years, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function. However, there is a lack of studies with treatment-naïve patients that would describe the initial effect of dual bronchodilation on respiratory and cardiovascular systems. In this study we aimed to evaluate the effect of initial dual bronchodilation on the quality of life, respiratory and cardiovascular systems in patients with newly-diagnosed chronic obstructive pulmonary disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 27 Sept 2023
- Start date
- 15 Apr 2021
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Lithuanian University of Health Sciences
- Diseases
- COPD
- NCT number
- NCT06072690
What you commit to
- Study type: Observational
- Planned participants: 80
- From 15 Apr 2021 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Present or previously treated lung cancer
- Previously diagnosed asthma
- Treatment with systemic glucocorticoids
Other illness
- Active lung infection
- Diagnosed interstitial lung disease
- Diagnosed chronic hypercapnic respiratory failure
- Unstable ischaemic heart disease
- Present cardiac arrhythmias
- Uncontrolled arterial hypertension
- Dementia and other mental states that determine patient's inability to consent
- Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion
Other
- Alpha-1 antitrypsin deficiency
- Pregnancy
Who the study is looking for
- Aged 40 years and older
- Smoking index of 10 pack-years and more
- Newly diagnosed chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC) less than 70 percent of predicted.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lithuanian University of Health Sciences Coordinator of this site? Confirm its status | Kaunas | Lithuania | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.